The Challenge of Defining End-of-Life in Glioblastoma

Glioblastoma multiforme remains one of the most aggressive malignancies of the central nervous system. Despite multimodal treatment involving surgical resection, radiotherapy, and temozolomide chemotherapy, patients experience a median overall survival of roughly fifteen months. Consequently, clinicians frequently confront significant dilemmas when identifying the terminal phase. Characterizing the transition to end-of-life in glioblastoma poses distinct challenges because patients face progressive neurological deficits alongside typical oncologic decline. Cognitive impairment, communication barriers, motor dysfunction, and personality changes often emerge early in disease recurrence. Therefore, healthcare providers struggle to pinpoint exactly when terminal palliative care should supersede active tumor-directed interventions. A recent systematic review led by Cyriaque Wagner-Ballon evaluated global literature to determine how researchers and clinicians define this critical timeframe. Their findings reveal profound heterogeneity across oncology and neurology practices worldwide. Without a consistent definition, clinicians risk initiating supportive interventions too late or continuing burdensome medical therapies unnecessarily. Addressing this clinical void requires establishing robust parameters to improve communication, clinical trials, and compassionate patient management.

Current Systematic Evidence and Literature Analysis

The investigators conducted an extensive systematic search across major biomedical databases, including PubMed, Web of Science, Science Direct, and PsychInfo, through January 2025. They examined studies evaluating adults with glioblastoma in the terminal palliative phase, alongside family caregivers and multidisciplinary healthcare teams. Out of eighteen eligible studies that met strict inclusion criteria, only eight investigations provided any descriptive criteria for the terminal stage. Furthermore, the reported parameters differed substantially across institutions and geographies. Notably, researchers frequently used arbitrary timeframes ranging from the final days to several months prior to death. In addition, none of the eighteen studies utilized validated prognostic scoring systems or standardized performance scales to demarcate this critical transition. Similarly, no identified investigations attempted to develop or prospectively validate a reproducible assessment instrument for neuro-oncology cohorts. As a result, existing literature relies heavily on retrospective chart reviews, subjective clinical impressions, or post-mortem classifications. This pronounced methodological gap hampers the reproducibility of clinical research and prevents reliable meta-analyses regarding palliative interventions in malignant neuro-oncology.

Neurological Decline Versus Systemic Oncologic Trajectories

General oncology guidelines often define the terminal interval through systemic markers, including rapid weight loss, cachexia, and acute visceral organ failure. However, glioblastoma multiforme follows an entirely different trajectory that confounds standard clinical assumptions. Patients frequently maintain stable systemic organ function while suffering extensive focal intracranial destruction. Neurological deterioration typically manifests as severe dysphagia, progressive aphasia, profound hemiparesis, intractable seizures, and altered levels of consciousness. Consequently, bedside clinicians cannot apply conventional palliative indices, such as the Palliative Prognostic Score, with sufficient accuracy. Moreover, high-dose corticosteroid therapy frequently masks progressive weakness while causing severe iatrogenic complications, including steroid-induced myopathy, metabolic instability, and psychiatric disturbances. Thus, caregivers and clinicians misinterpret temporary functional fluctuations as disease stabilization. Because primary brain tumors directly compromise speech and executive cognitive capacity, patients frequently lose decision-making autonomy before entering the final weeks. Therefore, the lack of objective indicators directly impairs timely goal-of-care conversations and deprives families of essential anticipatory guidance during neurological crises.

Clinical Ramifications for Palliative Planning

Ambiguity regarding the terminal trajectory leads to notable inconsistencies in medical practice. When teams cannot clearly define the terminal stage, they frequently delay discussions concerning advance directives, preferred place of death, and hospice referral. In contrast, timely integration of specialized palliative care improves symptom control and reduces caregiver distress. Delayed identification of end-of-life often causes inappropriate acute care interventions during the final weeks of survival. For instance, clinicians may continue ineffective cytotoxic agents, order frequent neuroimaging scans, or transfer comatose individuals to intensive care units during acute cerebral edema. Additionally, family caregivers carry immense psychological burdens without proper structural support. They witness behavioral disintegration and loss of personality without clear timelines or preparation. By standardizing clinical markers, neuro-oncology teams can systematically discontinue futile surveillance scans and streamline comfort-directed measures. Furthermore, establishing defined clinical parameters enables hospice teams to address common neuro-palliative emergencies proactively, including refractory status epilepticus, delirium, raised intracranial pressure, and severe neurogenic dysphagia.

Delphi Consensus as a Path Forward

To overcome current limitations, the systematic review authors advocate for a structured, international Delphi consensus approach. A Delphi process brings together neuro-oncologists, palliative care specialists, neurosurgeons, neurologists, specialized oncology nurses, and patient advocacy representatives. Through iterative survey rounds, experts can achieve formal agreement on composite criteria defining the terminal trajectory. Such criteria should integrate specific functional milestones, neurocognitive decline rates, radiographic parameters, and performance status measures. Moreover, future frameworks must incorporate input from caregivers to reflect patient-centered values and realistic home-care limits. Establishing rigorous definitions will substantially advance neuro-oncology clinical trials. Currently, researchers struggle to define uniform inclusion criteria for supportive care studies, creating heterogeneous cohorts and uninterpretable outcomes. Therefore, consensus-derived criteria will enhance comparative effectiveness research and establish standardized benchmarks for end-of-life quality metrics. Ultimately, a shared vocabulary across acute and community settings ensures cohesive multidisciplinary coordination throughout the patient journey.

Practical Recommendations for Multidisciplinary Teams

While awaiting formal consensus criteria, clinical teams must adopt practical strategies to support patients with advanced glioblastoma. First, clinicians should initiate advance care planning early following initial diagnosis or first recurrence, well before severe cognitive decline develops. Early discussions empower patients to document their preferences regarding artificial nutrition, mechanical ventilation, and resuscitation while capacity remains intact. Second, multidisciplinary teams must implement routine screening for neurocognitive shifts and caregiver burnout at every clinical follow-up. Third, healthcare professionals should provide clear prognostic guidance as functional dependence increases. Proactive education helps family members anticipate communication changes, sleepiness, and terminal seizures. Additionally, clinicians should establish straightforward protocols for managing dysphagia, ensuring seamless conversion from oral to subcutaneous or rectal antiseizure medications. Finally, primary oncology teams must foster close collaboration with home hospice and palliative services. Seamless interdisciplinary coordination prevents stressful emergency room admissions and honors patient wishes for dignity at the end of life.

Frequently Asked Questions

Why is determining the terminal phase uniquely difficult in glioblastoma?

Glioblastoma affects brain regions controlling cognition, personality, and language, often destroying decision-making capacity before physical demise. Furthermore, high-dose corticosteroids can mask neurological deterioration. Because patients rarely experience systemic visceral failure, clinicians struggle to predict life expectancy using conventional cancer models, which delays appropriate palliative transitions.

What did the systematic review uncover about current diagnostic criteria?

The systematic review evaluated eighteen eligible studies and revealed that only eight provided any definition of the terminal phase. Furthermore, none utilized validated scales or objective criteria. Definitions varied widely from days to months, underscoring a complete lack of standardized clinical consensus across published neuro-oncology literature.

How can neuro-oncology teams improve terminal care planning currently?

Clinicians should initiate advance care discussions promptly after diagnosis or tumor progression before cognitive capacity deteriorates. Additionally, teams should routinely assess caregiver fatigue, monitor progressive functional dependence, convert oral anticonvulsants to alternate routes proactively, and coordinate early hospice integration to prevent unnecessary emergency hospital admissions.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Wagner-Ballon C et al. Defining end-of-life in glioblastoma multiforme: a systematic review. J Neurooncol. 2025 Aug. doi: 10.1007/s11060-025-05051-8. PMID: 40301239.

Pace A, Dirven L, Koekkoek JAF, et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adult glioma patients. Lancet Oncol. 2017;18(6):e330-e340.

Sizoo EM, Pasman HR, Dirven L, et al. The end-of-life phase of high-grade glioma patients: A systematic review. Support Care Cancer. 2014;22(3):847-857.